// App-Quantinova.ai

3139 : Efficacy of Subsequent Novel Targeted Therapies, Including Repeated Venetoclax-Rituximab (VenR), in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Previously Treated with Fixed-Duration Venr in the Murano Study

Researchers

Presenter

  • Rosemary Anne Harrup

Principal Investigators

  • Carolyn Owen

  • James D'Rozario

  • Tadeusz Robak

  • Arnon P. Kater

  • Marco Montillo

  • Javier de la Serna

  • Marek Trnen

  • Su Young Kim

  • Edward Bataillard

  • Marcus Lefebure

  • Michelle Boyer

  • John F. Seymour

Medical Centers

  • Royal Hobart Hospital, Sandy Bay, Australia

  • The John Curtin School of Medical Research, Australian National University, Canberra, Australia

  • Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland

  • Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands

  • Department of Hematology and Oncology, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • Department of Internal Medicine, st Faculty of Medicine, Charles University, Central Military Hospital, Prague, Czech Republic

  • AbbVie, Inc., North Chicago, IL

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • Royal Melbourne Hospital, Peter MacCallum Cancer Centre and University of Melbourne,Melbourne,Australia

Locations

  • Australia

  • Canada

  • Poland

  • Netherlands

  • Italy

  • Spain

  • Czech Republic

  • United States

  • United Kingdom

Companies

  • Feng Chi Biotech Cor

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Venetoclax

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02005471

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved